So-Soo-Yoo®

A novel second generation FLT3 inhibitor levitrainorge.com.

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting Ambit Biosciences Corporation announced today that you will see multiple presentations evaluating AC220, a novel second generation FLT3 inhibitor, in AML at the 51st American Society of Hematology Annual Conference to be held in New Orleans, LA ,5-8 December, 2009. An oral display will highlight outcomes from an ongoing clinical Phase I monotherapy safety study in adults with severe myeloid leukemia levitrainorge.com http://levitrainorge.com . Additionally, non-clinical data will be presented evaluating the effect of AC220 monotherapy and in conjunction with chemotherapy. AML continues to be a disease with a substantial unmet medical need and brand-new therapies are urgently needed, said M.